NANOTECHNOLOGY-DRIVEN INNOVATIONS IN BRAIN TUMOR
Abstract
Brain tumours remain one of the most challenging neurological disorders to treat due to poor drug penetration across the blood–brain barrier (BBB), tumour heterogeneity, systemic toxicity, and multidrug resistance associated with conventional chemotherapy. Nanotechnology-based drug delivery systems have emerged as promising strategies to overcome these limitations by enhancing targeted delivery, improving bioavailability, and reducing adverse effects. Nanomaterials ranging from 1–100 nm, including polymeric nanoparticles, liposomes, micelles, extracellular vesicles, and inorganic carriers, enable controlled and site-specific drug release to tumour tissues.
Keywords:
Intracranial tumour, neurovascular barrier, nanotherapeutic system, nanoscale particles
Downloads
Download data is not yet available.
References
1. Biratu ES, Schwenker F, Ayano YM, Debelee TG. A survey of brain tumor segmentation and classification algorithms. J Imaging. 2021;7(9):179.
2. Van den Bent MJ, Weller M, Wen PY, Kros JM, Aldape K, Chang S. A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics. Neuro Oncol. 2017;19(5):614-624.
3. Miller KD, Ostrom QT, Kruchko C, Patil N, Tihan T, Cioffi G, et al. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin. 2021;71(5):381-406.
4. Brightman MW, Reese TS. Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol. 1969;40(3):648-677.
5. Nam L, Coll C, Erthal LCS, De la Torre C, Serrano D, Martínez-Máñez R, et al. Drug delivery nanosystems for the localized treatment of glioblastoma multiforme. Materials (Basel). 2018;11(5):779.
6. Loushambam B, Shimray MM, Khangembam R, Krishnaswami V, Vijayaraghavalu S. Nanomedicine-based advances in brain cancer treatment—A review. Neuroglia. 2025;6(3):28.
7. Ahmad F, Varghese R, Panda S, Ramamoorthy S, Areeshi MY, Fagoonee S, Haque S. Smart nanoformulations for brain cancer theranostics: Challenges and promises. Cancers (Basel). 2022;14(21):5389.
8. Treps L, Perret R, Edmond S, Ricard D, Gavard J. Glioblastoma stem-like cells secrete the pro-angiogenic VEGF-A factor in extracellular vesicles. J Extracell Vesicles. 2017;6(1):1359479.
9. Fortin D. Drug delivery technology to the CNS in the treatment of brain tumors: The Sherbrooke experience. Pharmaceutics. 2019;11(5):248.
10. Rao C. Evaluation of antiulcer activity of Picrasma quassioides Bennett aqueous extract in rodents. Vedic Res Int Phytomedicine. 2013.
11. Gindi S, Methra T, Chandu BR, Boyina R, Dasari V. Antiurolithiatic and in vitro anti-oxidant activity of leaves of Ageratum conyzoides in rat. World J Pharm Pharm Sci. 2013;2:636-649.
12. Nama S, Chandu BR, Awen BZ, Khagga M. Development and validation of a new RP-HPLC method for the determination of aprepitant in solid dosage forms. Trop J Pharm Res. 2011;10(4):489-495.
13. Kiranmai M, Renuka P, Brahmaiah B, Chandu BR. Vitamin D as a promising anticancer agent. Int J Res Pharm Chem. 2011;7(1):1-6.
14. Degapati RT. Novel approaches in transdermal drug delivery system. J Multidiscip Res. 2025;20-25.
15. Dara SR. An overview of the use of natural indicators in acid-base titrations. UPI J Pharm Med Health Sci. 2024:29-35.
2. Van den Bent MJ, Weller M, Wen PY, Kros JM, Aldape K, Chang S. A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics. Neuro Oncol. 2017;19(5):614-624.
3. Miller KD, Ostrom QT, Kruchko C, Patil N, Tihan T, Cioffi G, et al. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin. 2021;71(5):381-406.
4. Brightman MW, Reese TS. Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol. 1969;40(3):648-677.
5. Nam L, Coll C, Erthal LCS, De la Torre C, Serrano D, Martínez-Máñez R, et al. Drug delivery nanosystems for the localized treatment of glioblastoma multiforme. Materials (Basel). 2018;11(5):779.
6. Loushambam B, Shimray MM, Khangembam R, Krishnaswami V, Vijayaraghavalu S. Nanomedicine-based advances in brain cancer treatment—A review. Neuroglia. 2025;6(3):28.
7. Ahmad F, Varghese R, Panda S, Ramamoorthy S, Areeshi MY, Fagoonee S, Haque S. Smart nanoformulations for brain cancer theranostics: Challenges and promises. Cancers (Basel). 2022;14(21):5389.
8. Treps L, Perret R, Edmond S, Ricard D, Gavard J. Glioblastoma stem-like cells secrete the pro-angiogenic VEGF-A factor in extracellular vesicles. J Extracell Vesicles. 2017;6(1):1359479.
9. Fortin D. Drug delivery technology to the CNS in the treatment of brain tumors: The Sherbrooke experience. Pharmaceutics. 2019;11(5):248.
10. Rao C. Evaluation of antiulcer activity of Picrasma quassioides Bennett aqueous extract in rodents. Vedic Res Int Phytomedicine. 2013.
11. Gindi S, Methra T, Chandu BR, Boyina R, Dasari V. Antiurolithiatic and in vitro anti-oxidant activity of leaves of Ageratum conyzoides in rat. World J Pharm Pharm Sci. 2013;2:636-649.
12. Nama S, Chandu BR, Awen BZ, Khagga M. Development and validation of a new RP-HPLC method for the determination of aprepitant in solid dosage forms. Trop J Pharm Res. 2011;10(4):489-495.
13. Kiranmai M, Renuka P, Brahmaiah B, Chandu BR. Vitamin D as a promising anticancer agent. Int J Res Pharm Chem. 2011;7(1):1-6.
14. Degapati RT. Novel approaches in transdermal drug delivery system. J Multidiscip Res. 2025;20-25.
15. Dara SR. An overview of the use of natural indicators in acid-base titrations. UPI J Pharm Med Health Sci. 2024:29-35.
Published
20/06/2026
Statistics
19 Views | 20 Downloads
Citatons
How to Cite
Suryakalyanam, R. “NANOTECHNOLOGY-DRIVEN INNOVATIONS IN BRAIN TUMOR”. International Journal of Health Care and Biological Sciences, Vol. 7, no. 3, June 2026, pp. 11-15, https://www.saapjournals.org/index.php/ijhcbs/article/view/904.
Issue
Section
Review Articles
.